Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dose of L606 for Inhalation in Healthy Subjects

The primary objective of this study is to evaluate the Pharmacokinetics, Safety and Tolerability of L606 (Liposomal Treprostinil) Inhalation Solution in Single Ascending Dose study design in healthy volunteers.

Study Overview

• Status: Completed
• Conditions: Pulmonary Arterial Hypertension
• Intervention / Treatment: Device: L606 Inhalation System; Other: Placebo Solution; Drug: L606 (Liposomal Treprostinil) Inhalation Solution 51ug

Detailed Description

L606 (Liposomal Treprostinil) Inhalation Solution and dedicated inhalation system is developed by Pharmosa Biopharm Inc. intended to improve the inconvenience, as one of the greatest impediments to patient satisfaction to current inhaled treprostinil therapy. Pharmosa's liposomal technology offers sustained release of treprostinil which enable bid treatment instead of conventional qid treatment offered by current inhaled treprostinil therapy for treatment of patients with PAH (WHO Group 1).

• Study Type: Interventional
• Enrollment (Actual): 52
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Texas
    • Austin, Texas, United States, 78744
      • PPD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 46 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Males or females, of any race, 18 to 50 years of age, inclusive, at Screening.
2. Body mass index between 18.5 and 32.0 kg/m2, inclusive, at Screening.
3. In good health, determined by no clinically significant findings from medical history, physical examination, 12 lead ECG, vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is not acceptable) at Screening or Check in as assessed by the Investigator (or designee).
4. Ability of the subject to generate spirometry according to minimum ATS/ERS guidance criteria.
5. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception as detailed in Section 6.6.
6. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
7. Agree to abstain from consuming alcohol from 72 hours prior to Check-in.
8. Agree to refrain from strenuous exercise from 7 days prior to Check-in.
9. Agree to abstain from consuming foods and beverages containing poppy seeds, grapefruit, or Seville oranges from 7 days prior to Check-in.
10. Agree to abstain from consuming caffeine-containing foods and beverages from 48 hours prior to Check-in.
11. Agree to abstain from consuming carbonated drinks (including sparkling water and soda) from 48 hours prior to Check-in and until end of study.

Exclusion Criteria:

1. Clinically relevant abnormalities identified during Screening, physical examination, 12 lead ECG, or laboratory examinations.
2. Clinically significant history of hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, genitourinary, and/or musculoskeletal disease, glaucoma, psychiatric disorder, or any other chronic disease, whether controlled by medication or not.
3. History of anaphylaxis, significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless deemed not clinically significant by the Investigator (or designee).
4. History of postural hypotension, unexplained syncope, or hypertension.
5. History of asthma, chronic obstructive pulmonary disease (COPD), or reactive airways conditions or findings consistent with asthma or COPD on spirometry testing.
6. Blood pressure <90 mmHg systolic or <50 mmHg diastolic after supine for 5 minutes at Screening or Check in upon repeat testing.
7. Blood pressure >150 mmHg systolic or >90 mmHg diastolic after supine for 5 minutes at Screening or Check in upon repeat testing.
8. Pulse rate >100 bpm after supine for 5 minutes at Screening or Check-in upon repeat testing.
9. Have a pre-existing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs. Cholecystectomy is permitted if done at least 10 days before enrollment.
10. Use tobacco- or nicotine-containing products within 6 months prior to Check-in, or have a history of >1 pack cigarettes daily use over multiple years of smoking.
11. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.
12. Have a history of alcohol abuse or a history of or current impairment of organ function reasonably related to alcohol abuse.
13. Have a history of or current evidence of abuse of licit or illicit drugs or a positive urine screen for drugs of abuse.
14. Alcohol consumption of >21 units per week. One unit of alcohol equals 12 oz (360 mL) beer, 1.5 oz (45 mL) liquor, or 5 oz (150 mL) wine.
15. Positive urine drug screen (including alcohol and cotinine) at Screening and/or Check-in.
16. Positive hepatitis panel and/or positive human immunodeficiency virus test at Screening.
17. Participation in a clinical study involving administration of an investigational drug (new chemical entity) within 30 days prior to Check-in.
18. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's Wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
19. Use or intend to use any prescription medications/products within 14 days prior to Check-in with the exception of hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptives, unless deemed acceptable by the Investigator (or designee).
20. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
21. Use or intend to use any nonprescription medications/products or herbal supplements within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee). Use of nonsteroidal anti inflammatory drugs or aspirin is prohibited within 14 days prior to Check-in.
22. Receipt of blood products within 2 months prior to Check-in.
23. Donation of blood, plasma, and platelets, or the loss of a significant volume of blood (>450 mL) within 6 weeks prior to Screening.
24. Poor peripheral venous access.
25. Have a history of bleeding problems or abnormal bleeding tendencies.
26. Platelet or coagulation factor levels below the lower limit of normal, unless considered not clinically significant by the Investigator.
27. Have previously completed or withdrawn from this study or any other study investigating treprostinil, and have previously received the investigational product.
28. History of any recent infection within 2 weeks of Check-in.
29. In the opinion of the Investigator (or designee), should not participate in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: placebo; placebo group	Device: L606 Inhalation System; Single ascending dose; Other Names: Device: L606 Inhalation Solution; Other: Placebo Solution; Single ascending dose
Experimental: L606 Liposomal inhalation solution; Liposomal inhalation solution	Device: L606 Inhalation System; Single ascending dose; Other Names: Device: L606 Inhalation Solution; Drug: L606 (Liposomal Treprostinil) Inhalation Solution 51ug; Single ascending dose; Other Names: Drug: L606 (Liposomal Treprostinil) Inhalation Solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The number of treatment-emergent adverse events for L606 and placebo, including abnormal laboratory events	Frequency, severity and seriousness of adverse events (AE) including physical examination, incident of laboratory abnormalities, 12-lead ECG parameter and vital sign assessment	From Pre-dose to Day 10

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC0-2hr	area under curve from time zero to 2 hours postdose	From pre-dose to 24 hours post dose
AUC0-4hr	AUC from time zero to 4 hours postdose	From pre-dose to 24 hours post dose
AUC0-8hr	area under curve from time zero to 8 hours postdose	From pre-dose to 24 hours post dose
AUC0-12hr	area under curve from time zero to 12 hours postdose	From pre-dose to 24 hours post dose
AUC0-24hr	area under curve from time zero to 24 hours postdose	From pre-dose to 24 hours post dose
AUC0-tlast	AUC from time zero to the time of the last quantifiable concentration	From pre-dose to 24 hours post dose
AUC0-∞	area under curve from time zero to infinite	From pre-dose to 24 hours post dose
Cmax	maximum plasma concentration	From pre-dose to 24 hours post dose
tmax	time to Maximum Plasma Concentration	From pre-dose to 24 hours post dose
t1/2	time to half-life	From pre-dose to 24 hours post dose
CL/F	apparent total plasma clearance	From pre-dose to 24 hours post dose
Vz/F	apparent volume of distribution during terminal phase	From pre-dose to 24 hours post dose

Collaborators and Investigators

• Sponsor: Pharmosa Biopharm Inc.
• Collaborators: PPD Development, LP
• Investigators: Principal Investigator: Thomas L Hunt, MD, PhD, Pharmosa Biopharm Inc.PPD

Study record dates

Study Major Dates

• Study Start (Actual): November 9, 2018
• Primary Completion (Actual): September 20, 2019
• Study Completion (Actual): May 12, 2020

Study Registration Dates

• First Submitted: July 23, 2019
• First Submitted That Met QC Criteria: July 30, 2019
• First Posted (Actual): August 1, 2019

Study Record Updates

• Last Update Posted (Actual): August 5, 2025
• Last Update Submitted That Met QC Criteria: July 31, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Lung Diseases; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Antihypertensive Agents; Pharmaceutical Solutions; Treprostinil
• Other Study ID Numbers: PBI L606_2.0

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No